Abgenix has a unique method for the generation of antibodies useful in treating a number of diseases, including cancer. In early 2000, the company has performed the cancer is very good animal testing and changes in the early stages of human testing. Abgenix has to decide whether to sell the software development of large pharmaceutical company or enter into a joint venture to push the product forward. "Hide
abgenix and the xenomouse
by Robert J. Dolan Source: Harvard Business School 14 pages. Publication Date: 09 January 2001. Prod. #: 501061-PDF-ENG
Related Case Solutions & Analyses:
Hybrid Insights: Where the Quantitative Meets the Qualitative
Differences at Work: Sam (B)
Managing Segways Early Development
Volkswagen Navarra, 8th Collective Agreement (D)
Hospital for Special Surgery (A)
Laura Esserman – Creating the Climate for Change, Video
BUILDING THE CORPORATE LEARNING BRAND: THE STORY OF NIKE U
Sharp Corporation: Beyond Japan
Dr. Amita Joshi at Samuel Drugs Limited
Rebecca S. Halstead: Steadfast Leadership
